US 2026/0273039 A1Published application

Universal vaccine for african swine fever virus (asfv) infections

AssigneeDEI Biopharma

InventorMatthias Magoola

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to vaccine compositions for administration to domestic pigs (Sus scrofa domesticus), wild boars, warthogs, bush pigs, and giant forest hogs. In one embodiment, the present vaccine is designed to provide broad-spectrum immunity against all known genotypes (I-XXIV) and serotypes (1-8) of African Swine Fever Virus (ASFV) by incorporating highly conserved antigenic regions across multiple viral proteins. This multi-epitope vaccine construct is formulated to elicit both cellular (CD8+ and CD4+ T-cell) and humoral (antibody-mediated) immunity, ensuring cross-protection against diverse ASFV strains. By targeting conserved epitopes in structural (p72, p54, p30, CD2v) and non-structural proteins (MGF family, DNA replication enzymes, immune evasion factors), this vaccine aims to mitigate ASFV outbreaks globally, including regions affected by highly virulent Genotype II (Eastern Europe, Asia) and endemic strains in Africa. This universal antigen is optionally fused to a serum protein or a small synthetic peptide capable of binding to a serum protein in vivo to extend its half-life. In another embodiment, the invention, the antigen is produced by recombinant technology, or RNA technology to deliver the antigen in vivo or to produce it by a cell-free synthesis.

Claims9

Dependent claims

A universal multi-epitope vaccine formulation capable of inducing cross-protection against multiple genotypes (I-XXIV) and serotypes (1-8) of African Swine Fever Virus (ASFV), comprising:

a. a plurality of peptide epitopes selected from ASFV structural proteins (p72, p54, p30, CD2v) and non-structural proteins (MGF family, DNA replication enzymes, and immune evasion factors) to induce cellular (CD8+ and CD4+ T-cell) and humoral (antibody-mediated) immunity.
b. optimized linker sequences, wherein Cytotoxic T-lymphocyte (CTL) epitopes are connected via AAY (Ala-Ala-Tyr) linkers for MHC-I presentation, Helper T-lymphocyte (HTL) epitopes are connected via GPGPG (Gly-Pro-Gly-Pro-Gly) (SEQUENCE NO. 27), linkers for MHC-II processing, and B-cell epitopes are connected via KK (Lys-Lys) or GGGGS (Gly-Gly-Gly-Gly-Ser) (SEQUENCE NO. 29) linkers to enhance antibody recognition.
c. an adjuvant selected from the group consisting of TLR agonists (CpG ODN, Poly I:C, MPL), Saponin-based adjuvants (e.g., QS-21), and Oil-in-water emulsions (e.g., Montanide ISA) and Lipid nanoparticles (LNPs) for mRNA encapsulation.
d. a carrier system to enhance vaccine half-life and antigen uptake, wherein the antigen is fused to a serum protein or peptide selected from Albumin, Transferrin, or Fc fusion peptides.
e. a formulation produced by either recombinant expression of antigenic proteins or mRNA-based technology, including linear mRNA, self-replicating RNA, or circular RNA.
f. a pharmaceutical composition suitable for administration via Intramuscular (IM), subcutaneous (SC), intradermal (ID), oral, or intranasal spray delivery.”

3 more elements

Dependencies are inferred from the claim text.